Rosen Law Firm Announces Investigation Of Palomar Medical Technologies, Inc. In Connection With Its Sale To Cynosure, Inc. – PMTI

The Rosen Law Firm, P.A. is investigating the Board of Directors of Palomar Medical Technologies, Inc. (“Palomar” or the “Company”) (NASDAQ GS: PMTI) for possible breaches of fiduciary duty and other violations of state law in connection with its sale of the Company to Cynosure, Inc. (NASDAQ GS: CYNO).

If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.

Under the terms of the transaction, shareholders will receive $13.65 for each share of Palomar stock they own – $6.825 per share in cash and $6.825 per share in Cynosure common stock. The investigation relates to whether the price of $13.65 per share in cash and Cynosure stock is fair to public shareholders and whether PMTI’s Board breached its fiduciary duties in connection with the transaction.

If you own Palomar common stock and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010

If you liked this article you might like

Palomar Medical Technologies Inc. Stock Upgraded (PMTI)

Palomar Medical Technologies Inc. Stock Downgraded (PMTI)

Insiders Trading FURX, DSW, PMTI, CTL

Insiders Trading AKAM, CRI, PMTI, MSFT

8 Stocks Rising on Huge Volume